PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

PHARMApharmadossier

Topic

Specialty Drugs

High-cost specialty medications, payer coverage, access barriers, utilization management, and manufacturer support programs.

6 articles·Lives underSpecialty Pricing & Access·Last updated 2026-05-22

Pricing & Access· May 22, 2026 · 10 min read

AI-generated payer policies: how inclusion and exclusion criteria become more restrictive than the label

By Ran Chen#Payer Policy #Prior Authorization #Market Access

Pricing & Access· May 22, 2026 · 12 min read

AMCP dossier evidence gaps that weaken payer review for a new specialty drug

By Ran Chen#AMCP Dossier #Formulary #Payer Review

Pricing & Access· May 22, 2026 · 12 min read

ASP lag after launch: why buy-and-bill economics can break in the first quarters

By Ran Chen#Medicare Part B #ASP #Buy and Bill

Specialty· May 22, 2026 · 12 min read

Bridge Programs After Prior-Authorization Denial: Transition Risk and Compliance Boundaries

By Ran Chen#Patient Assistance #Prior Authorization #Specialty Pharmacy

Pricing & Access· May 22, 2026 · 13 min read

Copay accumulator and maximizer monitoring for manufacturer support teams

By Ran Chen#Copay Accumulator #Copay Maximizer #Specialty Drugs

Pricing & Access· May 22, 2026 · 17 min read

New-to-market payer blocks: the first 180 days after approval

By Ran Chen#Market Access #Payer Policy #Formulary Strategy